0453 GMT - Ebos's FY 2026 result was notable partly because of what it didn't include. "With the lack of another EPS downgrade, we are hopeful this result has marked the end of Ebos's downgrade cycle and investor confidence can start to rebuild," says Forsyth Barr analyst Ben Crozier. Still, Ebos hasn't delivered a return to its historic growth rate of 5%. Forsyth Barr estimates Ebos's organic growth rate in FY 2026 was 2%, largely reflecting competitive headwinds in its Community Pharmacy business. Forsyth Barr retains a neutral call on Ebos.